HomeGeneticsConditionGalactosialidosis
Back to Condition
Galactosialidosis
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Galactosialidosis

Galactosialidosis is a rare, inherited lysosomal storage disorder that affects multiple body systems, with symptoms and life expectancy varying significantly based on the age of onset.

Overview

Galactosialidosis is a condition that affects many areas of the body. The three forms of galactosialidosis are distinguished by the age at which symptoms develop and the pattern of features.

Early Infantile Form

Infants with this form are typically diagnosed between birth and 3 months of age and usually live to around 6 months. Features include:

  • Extensive swelling caused by fluid accumulation before birth (hydrops fetalis)
  • A soft out-pouching in the lower abdomen
  • Enlarged liver and spleen (hepatosplenomegaly)
  • Abnormal bone development (dysostosis multiplex)
  • Enlarged heart (cardiomegaly)
  • An eye abnormality called a cherry-red spot
  • Kidney disease that can progress to failure

Late Infantile Form

Symptoms typically begin around 2 years of age. This form is characterized by:

  • Short stature
  • Dysostosis multiplex
  • Hepatosplenomegaly
  • "Coarse" facial features
  • Intellectual disabilities
  • Hearing loss
  • Cherry-red spot

Juvenile/Adult Form

Symptoms typically begin around age 16, though the age of onset varies widely. This form is associated with a nearly normal life expectancy and includes:

  • Difficulty coordinating movements (ataxia)
  • Muscle twitches (myoclonus)
  • Seizures
  • Intellectual disabilities that worsen over time
  • Dark red spots on the skin (angiokeratomas)
  • "Coarse" facial features
  • Cherry-red spot
  • Vision loss and hearing loss

Causes

Variants in the CTSA gene cause all forms of galactosialidosis. This gene provides instructions for making a protein called cathepsin A, which is active in cellular compartments called lysosomes. Cathepsin A works with other enzymes to form a complex that breaks down sugar molecules attached to proteins or fats. It also plays a role in the formation of elastic fibers in the extracellular matrix.

CTSA gene variants interfere with the normal function of cathepsin A, causing other enzymes to become non-functional or break down prematurely. This leads to the accumulation of substances within the lysosomes, characteristic of this family of lysosomal storage disorders.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell must have a variant to cause the disorder. Parents of an affected individual typically carry one copy of the altered gene but do not show signs or symptoms.

Frequently Asked Questions

Infants need baseline echocardiography to assess cardiomegaly and valve function, followed by repeat scans every 1–3 months. Management includes diuretics for heart failure, ACE inhibitors if ventricular dysfunction develops, and referral to a pediatric cardiologist for possible surgical intervention.
Regular monitoring of serum creatinine, blood urea nitrogen, and urine protein every 3–6 months is essential. Hydration should be optimized, and nephrotoxic drugs avoided. Early referral to a pediatric nephrologist allows timely initiation of ACE inhibitors or angiotensin‑II blockers to reduce proteinuria and slow progression.
Since galactosialidosis is autosomal recessive, each sibling of an affected child has a 25 % chance of being affected, a 50 % chance of being a carrier, and a 25 % chance of being unaffected and not a carrier. Carrier testing for parents and at‑risk relatives, as well as pre‑implantation genetic diagnosis (PGD) or prenatal testing in future pregnancies, are recommended options.===
Ultrasound may show hydrops fetalis, enlarged liver/spleen, or a soft abdominal wall out‑pouch. If these findings appear, amniocentesis or chorionic villus sampling can be offered for molecular testing of the CTSA gene to confirm the diagnosis.
No FDA‑approved enzyme replacement exists yet, but experimental therapies such as gene‑transfer vectors targeting cathepsin A are under investigation in early‑phase trials. Families should discuss enrollment with a metabolic specialist and check registries like ClinicalTrials.gov for active studies in lysosomal storage disorders.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA